Cornea · 2008
Subconjunctival bevacizumab for corneal neovascularization.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Doctor Priyanka P, Bhat Pooja V, Foster C Stephen
Аннотация
PURPOSE: To describe whether subconjunctival bevacizumab decreases corneal neovascularization in patients with ocular surface inflammatory diseases.
METHODS: The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. Morphologic changes were assessed clinically by the same investigator at each visit.
RESULTS: Subconjunctival bevacizumab was well-tolerated without obvious corneal side effects. All 8 eyes of the 7 patients showed a reduction in the neovascularized area.
CONCLUSIONS: Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients.
METHODS: The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. Morphologic changes were assessed clinically by the same investigator at each visit.
RESULTS: Subconjunctival bevacizumab was well-tolerated without obvious corneal side effects. All 8 eyes of the 7 patients showed a reduction in the neovascularized area.
CONCLUSIONS: Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients.